Similar to the response to combination of anti‐RANKL plus anti‐PD‐1 antibodies, treatment with either 100 or 200 μg of the anti‐RANKL/PD‐1 BsAb significantly controlled established MC38‐OVAdim colon tumor growth compared with anti‐PD‐1 monotherapy (****P < 0.0001; Figure 4a). Here, TNFSF11 is linked to colonic neoplasm.